Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Clinical trial NCT04603001 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04603001
Sponsor: Eli Lilly and Company
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)Myeloproliferative Neoplasms (MPNs)

Start date: 2020-11-19
Primary completion: 2023-07-03
Enrollment: 260

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.